Market Closed -
Other stock markets
|
After market 20:59:57 | |||
82.2 EUR | -2.49% | 82.45 | +0.30% |
04-02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
03-12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+36.54% | 4.67B | |
+29.68% | 699B | |
+25.07% | 571B | |
-4.35% | 364B | |
+17.65% | 326B | |
+3.77% | 286B | |
+14.68% | 236B | |
+4.71% | 198B | |
-12.43% | 194B | |
-3.79% | 154B |
- Stock Market
- Equities
- ROVI Stock
- News Laboratorios Farmaceuticos Rovi, S.A.
- Laboratorios Farmaceuticos Rovi S A : Farmacéuticos Rovi FY20 Profit Climbs 55%; Dividend Raised